<DOC>
	<DOCNO>NCT01480388</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety tolerability JNJ-39758979 dose 10 , 30 , 100 , 300 mg/day compare placebo ( inactive medical substance ) patient active rheumatoid arthritis despite concomitant treatment methotrexate ( MTX ) .</brief_summary>
	<brief_title>A Dose Range Finding Study JNJ-39758979 Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate</brief_title>
	<detailed_description>This double-blind ( neither physician patient know patient receive JNJ-39758979 placebo ) , multicenter , randomize ( patient assign treatment chance ) , placebo-controlled , dose range find study JNJ-39758979 patient stable methotrexate treatment Week 24 . The study consist 4 period : screening period , 24-week placebo-controlled period , 24-week extension period , 5-week safety follow-up period . The duration participation study individual patient 59 week ( include screen ) . All patient randomly assign 1:1:1:1:1 ratio receive placebo JNJ-39758979 10 mg , 30 mg , 100 mg , 300 mg daily . At Week 24 , patient remain placebo group start receive JNJ-39758979 300 mg/day . Safety assessment evaluation determine efficacy JNJ-39758979 reduce sign symptom rheumatoid arthritis perform study visit . The extension safety follow-up period study continue Week 53 order ass safety maintenance efficacy patient .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Has diagnosis rheumatoid arthritis ( RA ) least 6 month screen . Positive test either anticyclic citrullinated peptide ( antiCCP ) antibody rheumatoid factor ( RF ) serum screen . Has active RA define persistent disease activity follow criterion : least 6 swollen 6 tender joint , serum CRP â‰¥ 0.70 mg/dL screening . Has treat tolerate methotrexate ( MTX ) treatment dosages 10 25 mg/week minimum 6 month prior screen must stable dose minimum 8 week prior screen Must postmenopausal premenopausal , must use acceptable form birth control Has complete least 5 day daily pain diary 10 day prior randomization . Has inflammatory disease RA , Lupus . Is currently receive treatment RA methotrexate , NSAIDS , oral corticosteroid prednisone , pain medicine . Has ever receive biologic agent rheumatic indication . Has current sign symptom liver insufficiency cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , psychiatric , metabolic disturbance severe , progressive , uncontrolled . Has moderate severe renal insufficiency Has recent ( within 2 month ) serious infection Has opportunistic infection . Has cancer within past 5 year ( except certain skin cervical condition ) Has abuse substance alcohol within past 2 year Has active Hepatitis B C infection Has active tuberculosis Has exposure tuberculosis without preventative treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Swollen tender joint</keyword>
	<keyword>Dose range finding study</keyword>
	<keyword>Concurrent treatment methotrexate</keyword>
</DOC>